Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.41 |
| ▸ | CCR5 | P51681 | 5/20 | 0.40 |
| ▸ | CCR2 | P41597 | 2/20 | 0.38 |
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | WDR91 | A4D1P6 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6412914 | 0.93 | CCR2 (0.44) | CCR5CCR2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6408483 | 0.93 | CCR2 (0.44) | CCR5CCR2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6413430 | 0.92 | CCR5 (0.41) | CCR5 | |
| SCHEMBL6412634 | 0.92 | CCR5 (0.42) | CCR5CCR2UTS2RRORCWDR91 | |
| SCHEMBL6408529 | 0.92 | CCR5 (0.40) | DRD2CCR5CCR2 | |
| Hydrochloric Acid SCHEMBL6412630 | 0.91 | CCR5 (0.41) | CCR5CCR2UTS2RRORCWDR91 | |
| SCHEMBL6409940 | 0.91 | CCR5 (0.42) | DRD2CCR5CCR2 | |
| SCHEMBL6409308 | 0.90 | DRD2 (0.42) | DRD2UTS2RWDR91AKT1 | |
| Hydrochloric Acid SCHEMBL6409876 | 0.89 | CCR5 (0.43) | CCR5CCR2UTS2RRORCWDR91 | |
| SCHEMBL6409321 | 0.89 | UTS2R (0.42) | DRD2CCR5UTS2RWDR91 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | claimed |
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR4, CXCR2 | DRD2 1775/4885CCR5 4/4885CCR2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.